GIMBHI’s daily mental health update — 7/17/26

🤝 PAX Health expands footprint, capability in New Jersey (Chris Larson, Behavioral Health Business) — 07/17/26
TL;DR: PAX Health acquired MAKRAF IME, adding statewide psychology and neuropsychology independent medical examination capability in New Jersey, its fourth deal since 2024 as the HCAP-backed provider continues its M&A growth spurt.

🧠 Zuranolone in the room: closing the gap in postpartum depression care (Leslie Williams, Psychiatric Times) — 07/16/26
TL;DR: Three years after zuranolone’s FDA approval as the first oral postpartum depression treatment, most eligible women still aren’t offered it; the author urges clinicians to close this familiarity gap given its rapid, days-not-weeks onset.

🍄 Lilly to acquire AtaiBeckley in up to $3.8 billion mental health deal (citybiz) — 07/16/26
TL;DR: Eli Lilly agreed to acquire AtaiBeckley for ~$2.8B upfront (up to $3.8B with milestones), gaining a pipeline of rapid-acting neuroplastogens, including BPL-003, an intranasal 5-MeO-DMT in Phase 3 for treatment-resistant depression.

🧠 MacKenzie Scott’s $20 million gift accelerates Active Minds’ national leadership in youth mental health (Active Minds) — 07/07/26
TL;DR: Active Minds received a $20M unrestricted gift from MacKenzie Scott its largest ever to scale youth-led mental health programs, leadership academies, and advocacy infrastructure nationwide.